skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Cellular Biomedicine Group (CBMG) CEO Bizuo (Tony) Liu differentiates plans for chimeric antigen receptor-T cell development in part by large-scale production in the company's home country, China. In an announcement on Jan. 3, the Shanghai-based immunotherapy and stem cell therapy company said it was expanding cell production in China to enable production of personalized CAR-T treatments in China for 10,000 patients annually. The company is focusing on becoming a leader in the area in China, but is manufacturing therapies according to both Chinese and US standards, Liu said in an interview at Biotech Showcase.








電話:+81 (0)3 6273 4260